Item 1
|
1(a)
|
Name of Issuer: Intra-Cellular Therapies, Inc.
|
|
1(b)
|
Address of Issuers Principal Executive Offices:
|
430 East 29th Street, Suite 900, New York, NY 10016
Item 2
2(a) Name of Person
Filing: BB Biotech AG (BB Biotech) on behalf of its wholly-owned subsidiary, Biotech Target N.V. (Biotech Target)
2(b) Address of Principal Business Office or, if none, Residence:
BB Biotech AG: Schwertstrasse 6, CH-8200 Schaffhausen, Switzerland
Biotech Target N.V.: Ara Hill Top Building, Unit A-5, Pletterijweg Oost 1, Curaçao
2(c) Citizenship: BB Biotech AG: Switzerland
Biotech Target N.V.: Curacao
2(d) Title of Class of Securities Common Stock, $0.0001 par value
2(e) CUSIP Number 46116X101
Item 3
If this statement is filed pursuant to
Rule 13d-1(b), or 13d-2(b) or (c), check whether the person filing is a:
a. ☐ Broker or Dealer registered under Section 15 of the Act.
b. ☐ Bank as defined in Section 3(a)(6) of the Act.
c. ☐ Insurance company as defined in Section 3(a)(19) of
the Act.
d. ☐ Investment company registered under section 8 of
the Investment Company Act of 1940.
e. ☐ An investment adviser
in accordance with Rule 13d-1(b)(1)(ii)(E);
f. ☐ An employee benefit plan or endowment fund in accordance with Rule 13d-1(b)(1)(ii)(F);
g. ☐ A
parent holding company or control person in accordance with Rule 13d-1(b)(1)(ii)(G);
h. ☐ A savings associations as defined in Section 3(b) of the
Federal Deposit Insurance Act (12 U.S.C. 1813);
i. ☐ A church
plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940;
j. ☐ Group, in accordance with Rule
13d-1(b)(1)(ii)(J).
4 of 7